Alto Neuroscience Inc’s shares reached a record high of $35.42 on Monday, capping a 793.91% surge over the prior 12 months as investors reacted to clinical progress and a $100 million equity offering.
The biotech’s stock closed at $36.25 on August 24, up 5.75% on the day, according to InvestingPro data. Year-to-date, Alto’s shares have gained 92.6%, while total return over the past year stands at 779%, reflecting strong investor appetite for neuroscience-focused drug developers.
The company priced a $100 million public offering at $26.48 per share, with proceeds earmarked for advancing ALTO-207, its lead drug candidate targeting treatment-resistant depression. The transaction is expected to close shortly, subject to customary conditions.
Clinical momentum has bolstered Alto’s valuation. An independent study published in Nature Medicine demonstrated that pramipexole, a dopaminergic agonist, significantly reduced anhedonia in patients with mood disorders. The trial was conducted by researchers at the University of Lund, providing mechanistic validation for Alto’s pipeline approach.
Analysts at H.C. Wainwright maintained a bullish stance, reiterating a buy rating and raising their price target to $55 from a prior level. The upgrade followed Alto’s disclosure of its development plan for ALTO-207, which includes Phase 2 clinical trials for treatment-resistant depression.
In a separate development, Alto appointed Andrew Miller, Ph.D., to its board. Miller brings neuroscience drug development expertise from Karuna Therapeutics, where he contributed to the development of COBENFY, a therapy for schizophrenia.
Despite the rally, InvestingPro flagged valuation risks, noting that Alto’s shares appeared overvalued relative to fair value estimates and were trading in overbought territory based on RSI metrics.
